Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing chronic obstructive pulmonary disease

Through the preparation of traditional Chinese medicine compositions, including antelope horns and goat horns, the lung function and inflammation damage problems in COPD treatment were solved, and the clinical symptoms and quality of life of COPD rats were significantly improved.

CN118948962APending Publication Date: 2024-11-15JIANGSU KANION PHARMA CO LTD

Patent Information

Application Number
CN202411194958.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat chronic obstructive pulmonary disease (COPD), especially in improving lung function and reducing inflammatory damage.

Method used

A Chinese medicine composition, including antelope horn, goat horn, fritillaria, rhubarb, scutellaria, ginger, gypsum, artificial beef and licorice, is prepared into different dosage forms by hydrolysis, decoction, extraction and concentration. , for oral or injectable administration.

Benefits of technology

Significantly improve the lung function of COPD rats, restore weight, reduce serum inflammatory factors, reduce lung and bronchial inflammation damage, reduce the secretion of acid mucin in the goblet cells of the bronchial epithelial, regulate the proportion of inflammatory cells in the lungs, and increase the proportion of inflammatory cells. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948962A_ABST
    Figure CN118948962A_ABST
Patent Text Reader

Abstract

The invention relates to an application of a traditional Chinese medicine composition in preparation of a medicine for treating or preventing chronic obstructive pulmonary disease (COPD), which is characterized in that the traditional Chinese medicine composition comprises 5-15 parts of antelope horn or 50-150 parts of cornu gorais, 10-60 parts of bulbus fritillariae ussuriensis, 15-60 parts of rheum officinale, 7-30 parts of scutellaria baicalensis, 7-30 parts of lapis chloriti, 10-50 parts of gypsum, 5-20 parts of calculus bovis factitius and 15-60 parts of liquorice. The traditional Chinese medicine composition has a certain treatment effect on COPD, and can significantly improve the lung function of a COPD rat and significantly reduce the level of serum inflammatory factors. Meanwhile, COPD (chronic obstructive pulmonary disease) rat lung and bronchitis injury can be remarkably relieved, secretion of bronchial epithelial goblet cell acidic mucoprotein is reduced, the proportion of lung proinflammatory cells is reduced, and the proportion of inflammatory inhibition cells is increased. In addition, the preparation method of the traditional Chinese medicine composition is simple, rapid, efficient and easy to operate. The prepared mixture, tablet, capsule, pellet and the like are convenient to carry and take.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicines, and relates to a new use of a traditional Chinese medicine composition, and specifically to an application of a traditional Chinese medicine composition in preparing a medicine for treating or preventing chronic obstructive pulmonary disease. Background Art

[0002] Chronic obstructive pulmonary disease (COPD) is a widespread chronic respiratory disease whose core feature is airflow limitation, which is usually irreversible. The main clinical manifestations of COPD include shortness of breath, persistent chronic cough, sputum production, and limited physical activity. Although the exact cause of COPD is not yet fully understood, it is known that a variety of factors such as long-term smoking, air pollution, occupational exposure (such as long-term inhalation of dust or chemicals) and genetic factors are closely related to the occurrence of the disease. These factors induce chronic inflammatory responses in the lungs and airways, leading to irreversible changes in lung structure and thus causing airflow limitation.

[0003] The symptoms of COPD tend to gradually worsen over several years. In the early stages, they may only present as a mild cough and a small amount of mucous sputum, but as the disease progresses, patients will experience significant dyspnea, especially when engaging in physical activity. Acute exacerbations may present with increased cough, increased sputum volume, and worsening dyspnea, sometimes accompanied by fever and body pain. In addition, patients may also experience symptoms such as chest pain, weight loss, fatigue, and shallow breathing. The diagnosis of COPD mainly relies on lung function tests, especially the ratio of forced expiratory volume (FEV1) to forced vital capacity (FVC) (FEV1 / FVC <70%) to determine the presence of airflow limitation. Depending on the severity of the disease, COPD is divided into four grades: A (mild), B (moderate), C (severe), and D (extremely severe).

[0004] In terms of treatment, the management of COPD involves a variety of methods such as drug therapy, oxygen therapy, and rehabilitation training. Drug therapy mainly includes inhaled glucocorticoids, long-acting β2 receptor agonists, anticholinergic drugs, and short-acting β2 receptor agonists. In recent years, the combination of Chinese and Western medicine has become an important direction for the treatment of COPD. Studies have shown that the combination of Chinese medicine syndrome differentiation and treatment can significantly improve the clinical symptoms of patients, reduce the number of acute exacerbations, and improve the quality of life on the basis of standardized Western medicine treatment. For example, a systematic review showed that Chinese medicine syndrome differentiation combined with standardized Western medicine treatment can significantly improve the assessment test (such as COPD Assessment Test, CAT) scores and St. George's Hospital Respiratory Questionnaire (SGRQ) scores of patients with COPD. Chinese medicine rehabilitation therapy has also shown good results in the treatment of stable COPD. For example, techniques such as Tai Chi, acupuncture, and breathing guidance can relieve patients' clinical symptoms, improve exercise endurance, and delay the decline of lung function, thereby improving patients' quality of life.

[0005] The present invention aims to provide a compound combination medicine for treating COPD, which exhibits unique therapeutic effects in the treatment of COPD and brings new hope to patients. Summary of the invention

[0006] The purpose of the present invention is to provide a compound combination drug for treating COPD to achieve effective treatment of COPD. Specifically,

[0007] The invention provides an application of a traditional Chinese medicine composition in preparing a drug for treating COPD, characterized in that the traditional Chinese medicine composition comprises: 5-15 parts of antelope horn or 50-150 parts of goat horn, 10-60 parts of flat fritillaria, 15-60 parts of rhubarb, 7-30 parts of scutellaria, 7-30 parts of celery, 10-50 parts of gypsum, 5-20 parts of artificial bezoar and 15-60 parts of liquorice.

[0008] Furthermore, the Chinese medicine composition includes: 8-12 parts of antelope horn or 80-120 parts of goat horn, 15-55 parts of Fritillaria thunbergii, 20-35 parts of rhubarb, 10-18 parts of scutellaria baicalensis, 10-18 parts of celite, 15-25 parts of gypsum, 8-12 parts of artificial bezoar, and 20-35 parts of liquorice.

[0009] Furthermore, the Chinese medicine composition includes: 9-10 parts of antelope horn or 90-100 parts of goat horn, 45-50 parts of Fritillaria thunbergii, 30-35 parts of rhubarb, 15-18 parts of scutellaria baicalensis, 15-18 parts of celite, 20-25 parts of gypsum, 9-10 parts of artificial bezoar, and 30-35 parts of licorice.

[0010] Preferably, the traditional Chinese medicine composition comprises: 9.45 parts of antelope horn, 47.25 parts of Fritillaria thunbergii, 31.5 parts of rhubarb, 15.75 parts of scutellaria baicalensis, 15.75 parts of celite, 23.62 parts of gypsum, 9.45 parts of artificial bezoar, and 31.5 parts of liquorice.

[0011] Preferably, the Chinese medicine composition comprises: 94.5 parts of goat horn, 47.25 parts of Fritillaria thunbergii, 31.5 parts of rhubarb, 15.75 parts of scutellaria baicalensis, 15.75 parts of celite, 23.62 parts of gypsum, 9.45 parts of artificial bezoar, and 31.5 parts of liquorice.

[0012] The present invention also provides a use of any of the above-mentioned Chinese medicine compositions in the preparation of drugs for treating or preventing lung and / or bronchial inflammation.

[0013] Specifically, the drug is selected from an oral dosage form, an injection dosage form or an external administration preparation.

[0014] Specifically, the medicine is selected from decoctions, tablets, capsules, granules, pills, injections, decoctions, suspensions, dispersants, syrups, suppositories, gels, aerosols, patches, and oral liquids.

[0015] Among them, the composition of the present invention described above can be prepared by directly grinding several medicinal materials into powder according to traditional methods, or by obtaining extracts through conventional means so as to be made into different dosage forms, thereby obtaining better therapeutic effects and being more conducive to the preparation of modern pharmaceutical dosage forms.

[0016] Preferably, the method for preparing the traditional Chinese medicine composition as described above comprises the following steps: pounding antelope horn or goat horn into silk, hydrolyzing it with an alkaline aqueous solution, filtering, and concentrating the filtrate; crushing bluestone and gypsum into coarse powder, heating and boiling with water, filtering, and concentrating the filtrate; extracting artificial bezoar with 70% ethanol, filtering, and concentrating the filtrate; boiling the remaining medicinal materials with water, concentrating the filtrate and centrifuging it, adding ethanol to the supernatant for precipitation, letting it stand, taking the supernatant, filtering, and concentrating the filtrate; mixing the above concentrated solutions to obtain the product.

[0017] More specifically, the composition as described above is extracted using the following method:

[0018] Antelope horn or goat horn is pounded into silk, hydrolyzed with alkaline aqueous solution and refluxed twice, the two filtrates are combined and concentrated; bluestone and gypsum are crushed into coarse powder, heated and decocted with water twice, filtered, the two filtrates are combined, and the relative density is 1.01-1.04 (75°C-85°C); artificial bezoar is extracted with 70% ethanol by reflux twice, filtered, the two filtrates are combined, ethanol is recovered under reduced pressure, and the relative density is 1.02-1.05 (75°C-85°C); the other four herbs such as flat fritillaria are decocted with water twice, filtered, the two filtrates are combined, and the relative density is 1.10 (85°C), centrifuged, ethanol is added to the supernatant to precipitate, let stand, take the supernatant, filter, reduce pressure to recover ethanol, and concentrate to a relative density of 1.08 (85°C); the above concentrated solutions are mixed to obtain.

[0019] The present invention also provides a method for preparing the oral liquid, namely, mixing the above-mentioned mixed concentrated liquid with 0.2% stevioside, adding water to 1000ml, stirring, boiling for 40 minutes, refrigerating for not less than 48h, filtering, adding water to the filtrate to 1000ml, adjusting the pH value to 8.0-9.0, filling, and sterilizing to obtain the oral liquid.

[0020] The above preparation method can be used to obtain a liquid preparation. If a solid preparation is to be prepared, a pharmaceutical excipient can be added to the liquid medicine to prepare the medicine selected from decoctions, tablets, capsules, granules, pills, injections, decoctions, suspensions, dispersants, syrups, suppositories, gels, aerosols, patches, and oral liquids.

[0021] The present invention provides a compound combination medicine for treating COPD. The research results confirm that the compound combination medicine has a certain therapeutic effect on the rat COPD model, including significantly improving the lung function of COPD rats, restoring the body weight of rats, and significantly reducing the level of serum inflammatory factors. At the same time, it can significantly reduce lung and bronchial inflammatory damage, reduce the secretion of acidic mucin of bronchial epithelial goblet cells, reduce the proportion of pro-inflammatory cells in the lungs, and increase the proportion of anti-inflammatory cells. It is proved that the Chinese medicine composition has a therapeutic effect on COPD. Moreover, the preparation method of the compound combination medicine for treating COPD is simple, fast, efficient, and easy to operate. The prepared mixture, tablets, capsules, pellets, etc. are easy to carry and convenient to take. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Weight statistics of rats in each group. (A) Weight growth curve of rats during the experiment; (B) Weight gain of rats in the first stage of COPD modeling; (C) Weight gain of rats in the second stage of COPD; (D) Weight gain of rats in the second stage of COPD; (E) Weight statistics of rats in each group at the end of the experiment. The results are expressed as Mean±SD, **P<0.01, ****P<0.0001.

[0023] Figure 2 After the first stage of modeling, the lung function test results of rats in each group were as follows. (A) The peak expiratory flow rate (PEF) of rats in each group; (B) The exhaled 50% FVC volume flow rate (FEF) of rats in each group

[0024] 50%); (C) Tidal volume (VC) of rats in each group. The results are expressed as Mean±SD, **P<0.01, ***P<0.001, ****P<0.0001.

[0025] Figure 3 Pulmonary function test results of rats in each group after administration. (A) Peak expiratory flow rate (PEF) of rats in each group; (B) Forced expiratory volume in 0.3 seconds (FEV 0.3) of rats in each group; (C) Forced expiratory volume (FVC) of rats in each group; (D) FEV0.3 / FVC ratio of rats in each group. Results are expressed as Mean±SD, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0026] Figure 4 Detection of inflammatory factor levels in the serum of rats in each group. (A) TNF-α level in the serum of rats in each group; (B) IL-6 level in the serum of rats in each group; (C) NE level in the serum of rats in each group; (D) CRP level in the serum of rats in each group. The results are expressed as Mean±SD, **** P<0.0001.

[0027] Figure 5 HE staining of lung tissue and bronchus of rats in each group. (A) Representative images of HE staining of lung tissue of rats in each group; (B) Representative images of HE staining of bronchus of rats in each group. (C) Statistical analysis results, the results are expressed as Mean±SD, **P<0.01, ****P<0.0001.

[0028] Figure 6 AB-PAS staining of bronchus of rats in each group. (A) Representative images of AB-PAS staining of bronchus of rats in each group. The results are expressed as Mean±SD, **P<0.01, ***P<0.001.

[0029] Figure 7Proportions of inflammatory cell groups in the lung tissue of rats in each group. (A) Proportion of Th1 cells in the lung tissue of rats in each group; (B) Proportion of Th2 cells in the lung tissue of rats in each group; (C) Proportion of Th1 / Th2 cells in the lung tissue of rats in each group; (D) Proportion of Th17 cells in the lung tissue of rats in each group; (E) Proportion of Treg cells in the lung tissue of rats in each group; (F) Proportion of Th17 / Treg cells in the lung tissue of rats in each group. The results are expressed as Mean±SD, *P<0.05, ***P<0.001, ****P<0.0001. DETAILED DESCRIPTION

[0030] As mentioned above, the present invention aims to provide a use of a Chinese medicine composition in preparing a drug for treating or preventing COPD. The following will be described in detail in conjunction with the contents of specific experiments.

[0031] The following experiments, if no specific conditions are specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The APIs or excipients, reagents or instruments used, if the manufacturer is not specified, are all conventional products that can be purchased commercially. Unless otherwise specified, all percentages, ratios, proportions or parts are by weight.

[0032] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention.

[0033] Example 1 Preparation of oral liquid preparation of Chinese medicine composition

[0034] 94.5g of goat horn was pounded into silk, hydrolyzed with alkaline aqueous solution and refluxed twice, the two filtrates were combined and concentrated; 15.75g of chlorite and 23.62g of gypsum were crushed into coarse powder, heated and boiled in water twice, filtered, the two filtrates were combined and concentrated to a relative density of 1.01-1.04 (75℃-85℃); 9.45g of artificial bezoar was extracted twice with 70% ethanol by reflux, filtered, the two filtrates were combined, ethanol was recovered under reduced pressure, and concentrated to a relative density of 1 .02~1.05(75℃~85℃); the other four herbs, 47.25g of Fritillaria thunbergii, 31.5g of Rhubarb, 15.75g of Scutellaria baicalensis, and 31.5g of Licorice, are decocted twice with water, filtered, the two filtrates are combined, concentrated to a relative density of 1.10(85℃), centrifuged, ethanol is added to the supernatant to precipitate, allowed to stand, the supernatant is taken, filtered, ethanol is recovered under reduced pressure, and concentrated to a relative density of 1.08(85℃); the above concentrated solutions are mixed to obtain the product.

[0035] The above concentrate is mixed with 0.2% stevioside, water is added to 1000ml, stirred, boiled for 40 minutes, refrigerated for not less than 48h, filtered, water is added to the filtrate to 1000ml, the pH value is adjusted to 8.0-9.0, potted, sterilized, and the oral liquid preparation is obtained.

[0036] Therapeutic Effect of Traditional Chinese Medicine Composition in Experimental Example 2 on Rat COPD Model Prepared by Cigarette Smoke Combined with LPS

[0037] 1 Experimental Materials

[0038] 1.1 Experimental Animals

[0039] SPF-grade SD rats (male, 180 - 220 g, certificate number: SCXK(Shanghai)2023 - 0009) were purchased from Shanghai Bikai Keyi Biotechnology Co., Ltd. and raised in an environment with a temperature of 21 - 25 °C, humidity of 40% - 70%, and a 12-hour day-night cycle, with free access to food and water.

[0040] 1.2 Test Drugs

[0041] The traditional Chinese medicine composition prepared in Example 1 was provided by Jiangsu Kanion Pharmaceutical Co., Ltd., and the positive drug dexamethasone was purchased from Shanghai Sangon Biotech Co., Ltd. (product number: A601187 - 0005).

[0042] 1.3 Experimental Instruments

[0043] The information of the main experimental instruments is shown in Table 1.

[0044] Table 1 List of Experimental Instruments

[0045]

[0046]

[0047] 1.4 Experimental Reagents and Consumables

[0048] The information of the main experimental reagents and consumables is shown in Table 2.

[0049] Table 2 Experimental Reagents

[0050]

[0051] 2 Experimental Methods

[0052] 2.1 Experimental Grouping

[0053] SD rats were randomly divided into 6 groups (n = 8): normal control group (Group C), COPD model group (Group M), low-dose traditional Chinese medicine composition group (Group ML), medium-dose traditional Chinese medicine composition group (Group MM), high-dose traditional Chinese medicine composition group (Group MH), and positive drug group (Group MP).

[0054] 2.2 Establishment of Animal Model and Drug Intervention

[0055] Wistar rats were adaptively fed for 7 days and had free access to feed and water. Subsequently, two stages of modeling were performed. COPD model establishment (first stage of modeling): 8 rats were randomly selected as the normal control group, and the remaining rats were nasally instilled with 1 mg / kg LPS solution, twice a week, for 8 weeks. The normal control group rats were instilled with an equal volume of saline (no cigarette smoke exposure on the day of LPS instillation). In addition to the normal control group rats placed in a well-ventilated room, the remaining rats were exposed to cigarette smoke using a multi-channel smoke exposure system, 10 cigarettes / time, 30 minutes / time, 2 times / d, each time interval greater than 3 hours, for 8 weeks.

[0056] Pulmonary function test: After the first stage of modeling, the tidal volume (VC), peak expiratory flow rate (PEF), 50% FVC exhaled volume flow rate (FEF 50%) and other lung function indicators of rats in each group were measured. If the indicators were significantly lower than those of the control group, the modeling was considered successful. 40 rats with successful modeling were randomly selected as the model group (M group) and the test smoke groups (ML, MM, MH and MP groups), with 8 rats in each group.

[0057] Drug intervention stage (the second stage of modeling): Each group started the second stage (drug intervention) on the second day after the end of the first stage of modeling. The low-, medium- and high-dose groups of the Chinese medicine composition were gavaged at a dose of 2.02 g of crude drug / kg, 4.04 g of crude drug / kg, and 8.08 g of crude drug / kg, respectively. The positive drug group was gavaged at a dose of 0.2 mg / kg / d for 7 consecutive days.

[0058] 2.3 General behavioral observations

[0059] During the COPD modeling period (the first stage), the body weight of rats in each group was recorded once a week; from the second stage of the experiment to the end point, the body weight of rats in each group was recorded once a day.

[0060] 2.4 Pulmonary function test

[0061] After the administration, the rats were fasted but not watered for 12 h, and the rats were intubated under intraperitoneal anesthesia. The forced expiratory volume in 0.3 seconds (FEV 0.3), forced expiratory volume (FVC), and peak expiratory flow (PEF) were measured using a small animal pulmonary function analysis system, and the FEV 0.3 / FVC ratio was calculated.

[0062] 2.5 Sample collection

[0063] Rats were killed, blood was collected from the abdominal aorta, centrifuged, and the supernatant was collected and placed in a -80°C refrigerator for later use. The thorax was quickly opened to separate the bronchi and lungs. The left middle lobe and bronchus of the rat were taken for HE staining and AB-PAS staining, and the left lower lobe and right lung were used for flow cytometry detection.

[0064] 2.6HE and PAS staining

[0065] (1) Fixed

[0066] The middle lobe and bronchial tissues of the lung were fixed with 4% paraformaldehyde for 24 hours and then transferred to 70% alcohol for preservation. The fixed specimens were removed and cut into small samples with a thickness of 3-5 mm with a scalpel, placed in an embedding box, and marked with a pencil. The fixed tissues were dehydrated in a dehydrator according to the steps: 50% ethanol for 2 hours → 60% ethanol for 2 hours → 70% ethanol for 2 hours → 80% ethanol for 2 hours → 90% ethanol for 1 hour → 95% ethanol for 2 hours → 95% ethanol for 2 hours → 100% ethanol for 3 hours → 70% ethanol for 3 hours → xylene for 5 minutes → xylene for 1 hour → paraffin for 1 hour → paraffin for 1 hour.

[0067] (2) Paraffin embedding

[0068] Open the embedding machine 2 hours in advance and wait for the paraffin to melt completely. Pour the dehydrated tissue into the melted paraffin in the embedding machine. Take out the embedding mold, fill it with liquid paraffin, and put the tissue in after the temperature stabilizes. Adjust and fix the tissue in the center of the embedding mold, cover the embedding box, and put it in the cold table after it cools down slightly. After the paraffin cools and sets, take out the tissue wax block for the next experiment.

[0069] (3) Slicing

[0070] Place the trimmed tissue wax block on the clamping table of the slicer. Fix the blade on the knife clamp with the blade facing up, and adjust the angle and position of the tissue wax block and the blade. Adjust the thickness regulator to 10μm for rough cutting. When the complete tissue is visible on the cut wax strip, adjust the thickness regulator to 4μm again for fine cutting. Put the cut wax slices into cold water and 42℃ hot water in turn to flatten them. Pick up the slices with a slide and dry them.

[0071] (4) HE staining

[0072] Place the prepared paraffin sections of lung and bronchial tissue in an electric constant temperature drying oven and bake at 60℃ for 3h. Dewax the dried paraffin sections with conventional xylene, hydrate with gradient ethanol, and wash with distilled water. Stain the nucleus with hematoxylin for 2min, differentiate with hydrochloric acid alcohol for a few seconds, and wash with water to return to blue. Stain the sections with eosin solution for 1min, and wash with water to rinse off the residual stain. Dehydrate and dry the sections with gradient alcohol, make them transparent with xylene, and seal them with neutral gum. Observe the lung tissue and take pictures under a 200× field of view, and observe the bronchi and take pictures under a 400× field of view.

[0073] (5) PAS staining

[0074] During the processing and staining of tissue sections, the prepared paraffin sections were first baked in an electric constant temperature drying oven at 60°C for 90 minutes to complete the baking step. Subsequently, dewaxing and hydration treatment were carried out, and the sections were immersed in xylene I solution and xylene II solution in turn for 10 minutes each, and then passed through 100%, 95%, 80%, and 75% gradient ethanol solutions in turn, each for 5 minutes, and finally immersed in double distilled water I and double distilled water II, also for 5 minutes each. After the oxidant was added to the tissue sections in the dark box, they were placed at room temperature for 5 minutes, rinsed with running water, and rinsed twice with distilled water. Next, Schiff staining solution was added to the tissue, and it was stained at room temperature for 20 minutes away from light, and then rinsed with running water for 10 minutes. Hematoxylin staining solution was used to stain the cell nucleus for 2 minutes, and then placed in hydrochloric acid alcohol acid differentiation solution for differentiation for 5 seconds, and the cell nucleus was rinsed with running water to return to blue. The tissue dehydration steps include immersing the sections in double distilled water I and double distilled water II in turn for 5 minutes each time, then passing through 75%, 80%, 95%, and 100% gradient ethanol solutions for 5 minutes each level, and finally immersing in xylene I solution and xylene II solution in turn for 5 minutes each time. When sealing the slides, place the slides at room temperature to dry, add neutral resin for sealing, and be careful to avoid sealing too many bubbles. Finally, the sealed slides were placed under a 200× field of view for observation and filming to count the proportion of PAS-positive areas.

[0075] 2.7ELISA test

[0076] The expression levels of cytokines such as TNF-α, IL-6, neutrophil elastase (NE), and C-reactive protein (CRP) in serum were determined according to the given protocol of the ELISA kit.

[0077] 2.8 Statistical methods

[0078] The data were analyzed and plotted using GraphPad Prism 9 (Version 9.4.0), and Adobe Illustrator 2022 (Version 26.3.1) was used to organize and combine the figures. All data are expressed as mean ± SD, and the statistical differences between the groups were tested using Two-way ANOVA and One-way ANOVA. P values ​​less than 0.05 were considered to be significantly different.

[0079] 5. Experimental Results

[0080] (1) Effects of Chinese herbal medicine combination on body weight and phenotype of COPD rats

[0081] The weight records of the rats in each group showed that compared with the normal control group, the weight of the rats in each group decreased significantly after modeling, and the intervention of the Chinese medicine composition could improve the symptoms of weight loss in the rats ( Figure 1 ).

[0082] (2) Effect of Chinese herbal medicine combination on respiratory function of COPD rats

[0083] After the first stage of modeling, the lung function of rats in each group was tested. The results showed that compared with the normal control group, the PEF, FEF 50% and VC of rats in each group after modeling were significantly reduced ( Figure 2 ), which can be used to determine the success of COPD modeling.

[0084] In addition, in the second stage of the experiment, the lung function of rats in each group was tested after 1 week of different drug treatment. The results showed that the peak expiratory flow rate (PEF), forced expiratory volume in 0.3 seconds (FEV 0.3), forced expiratory volume (FVC), and FEV0.3 / FVC ratio of rats in the model group were significantly reduced ( Figure 3 ). In contrast, compared with the model group, the tested Chinese medicine composition can increase the PEF, FEV 0.3, FVC, and FEV0.3 / FVC ratio of COPD rats in a dose-dependent manner, and the statistical analysis results of the high-dose group and the medium-dose group are more obvious ( Figure 3 ).

[0085] (3) Effect of Chinese medicine combination on serum inflammatory factor levels in COPD rats

[0086] Compared with the normal control group, the levels of TNF-α, IL-6, NE, and CRP in the serum of the COPD model group rats were significantly increased. On the contrary, compared with the model group, the Chinese medicine composition can increase the levels of TNF-α, IL-6, NE, and CRP in the serum of COPD rats in a dose-dependent manner. The statistical analysis results of the high-dose group and the medium-dose group were significantly different from those of the model group, and the therapeutic effect of the high-dose group was equivalent to that of the positive control drug ( Figure 4 ), suggesting that the Chinese medicine composition can alleviate systemic inflammation in rats.

[0087] (4) Effects of Chinese medicine combination on lung and bronchial inflammation in COPD rats

[0088] Compared with the normal control group, the alveoli in the lung tissue of the rats after modeling were significantly enlarged, the number of alveoli in the same field of view decreased, and some alveolar walls were broken and fused; in addition, bronchial cilia fell off, adhered, and disappeared, and the secretion of acidic mucin in the goblet cells of the bronchial epithelium of the rats was significantly increased ( Figure 5 and Figure 6 Compared with the model group, the high-dose Chinese medicine combination intervention can alleviate the above-mentioned lung inflammation damage and significantly reduce the secretion of acidic mucin in bronchial epithelial goblet cells ( Figure 5 and Figure 6 ).

[0089] (5) Effect of Chinese medicine combination on the proportion of inflammatory cells in lung tissue of COPD rats

[0090] Compared with the normal control group, the proportion of Th1 and Th17 cells in the lungs of rats in the model group increased significantly, indicating that the lungs showed strong inflammation after modeling. Intervention with medium and high doses of the Chinese medicine composition significantly reduced the proportion of Th1 and Th17 cells in the lungs, showing a dose-dependent manner. The proportion of Th2 cells in the lungs of rats in the model group decreased significantly. Intervention with medium and high doses of the Chinese medicine composition increased the proportion of Th2 cells, and the Th1 / Th2 ratio also decreased significantly ( Figure 7 ), suggesting that the Chinese medicine composition helps to reduce the proportion of pro-inflammatory cells in the lungs, increase the proportion of anti-inflammatory cells, and alleviate inflammation of lung tissue.

[0091] 6. Experimental conclusion

[0092] The medium dose (4.04g crude drug / kg) and high dose (8.08g crude drug / kg) of the Chinese medicine composition can significantly improve the lung function indicators of COPD rats, including significantly improving the PEF, FEV0.3, FVC, and FEV0.3 / FVC ratio of COPD rats. At the same time, the Chinese medicine composition can significantly reduce lung and bronchial inflammatory damage, reduce the secretion of acidic mucin of bronchial epithelial goblet cells, and reduce the proportion of Th1 and Th17 cells in lung tissue, and increase the proportion of Th2 cells. In summary, this experiment proves that the Chinese medicine composition has a therapeutic effect on COPD.

[0093] The above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. Use of a Chinese medicine composition in the preparation of a drug for treating or preventing chronic obstructive pulmonary disease, characterized in that: The traditional Chinese medicine composition comprises: 5-15 parts of antelope horn or 50-150 parts of goat horn, 10-60 parts of flat fritillaria, 15-60 parts of rhubarb, 7-30 parts of scutellaria, 7-30 parts of celery, 10-50 parts of gypsum, 5-20 parts of artificial bezoar and 15-60 parts of liquorice.

2. The application according to claim 1, characterized in that: The traditional Chinese medicine composition comprises: 9-10 parts of antelope horn or 90-100 parts of goat horn, 45-50 parts of flat fritillaria, 30-35 parts of rhubarb, 15-18 parts of scutellaria, 15-18 parts of celery, 20-25 parts of gypsum, 9-10 parts of artificial bezoar and 30-35 parts of liquorice.

3. The application according to claim 1, characterized in that: The traditional Chinese medicine composition comprises: 9.45 parts of antelope horn or 94.5 parts of goat horn, 47.25 parts of flat fritillaria, 31.5 parts of rhubarb, 15.75 parts of scutellaria, 15.75 parts of celery, 23.62 parts of gypsum, 9.45 parts of artificial bezoar and 31.5 parts of liquorice.

4. The use according to any one of claims 1 to 3, characterized in that: The drug is selected from oral dosage forms, injection dosage forms or external administration preparations.

5. The use according to claim 4, characterized in that: The medicine is selected from decoctions, tablets, capsules, granules, pills, injections, decoctions, suspensions, dispersants, syrups, suppositories, gels, aerosols, patches, and oral liquids.

6. The use according to any one of claims 1 to 3, characterized in that: The preparation method of the traditional Chinese medicine composition comprises the following steps: taking antelope horns or goat horns, pounding them into silk, hydrolyzing them with an alkaline aqueous solution, filtering, and concentrating the filtrate; taking bluestone and gypsum, crushing them into coarse powder, heating and boiling them with water, filtering, and concentrating the filtrate; taking artificial bezoar, extracting them with 70% ethanol, filtering, and concentrating the filtrate; boiling the remaining medicinal materials with water, concentrating the filtrate and centrifuging it, adding ethanol to the supernatant to precipitate it, letting it stand, taking the supernatant, filtering, and concentrating the filtrate; mixing the above concentrated solutions to obtain the traditional Chinese medicine composition.

7. The use according to any one of claims 1 to 3, characterized in that: The preparation method of the medicine comprises: The goat horn 94.5g was pounded into silk, hydrolyzed with an alkaline aqueous solution and refluxed twice, the two filtrates were combined and concentrated; 15.75g of chlorite and 23.62g of gypsum were crushed into coarse powder, heated and boiled with water twice, filtered, the two filtrates were combined, and concentrated to a relative density of 1.01-1.04 (75°C-85°C); 9.45g of artificial bezoar was extracted twice with 70% ethanol by reflux, filtered, the two filtrates were combined, ethanol was recovered under reduced pressure, and concentrated to a relative density of 1.02~1.05 (75℃~85℃); the other four herbs, 47.25g of Fritillaria brevis, 31.5g of Rhubarb, 15.75g of Scutellaria baicalensis, and 31.5g of Licorice, are decocted twice with water, filtered, the two filtrates are combined, concentrated to a relative density of 1.10 (85℃), centrifuged, ethanol is added to the supernatant to precipitate, allowed to stand, the supernatant is taken, filtered, ethanol is recovered under reduced pressure, and concentrated to a relative density of 1.08 (85℃); the above concentrated solutions are mixed to obtain. Mix the above concentrate with 0.2% stevioside, add water to 1000ml, stir evenly, boil for 40 minutes, refrigerate for not less than 48h, filter, add water to the filtrate to 1000ml, adjust the pH value to 8.0-9.0, fill and sterilize.

8. Use of a Chinese medicine composition in the preparation of a drug for treating or preventing lung or bronchial inflammation, characterized in that: The traditional Chinese medicine composition comprises: 5-15 parts of antelope horn or 50-150 parts of goat horn, 10-60 parts of flat fritillaria, 15-60 parts of rhubarb, 7-30 parts of scutellaria, 7-30 parts of celery, 10-50 parts of gypsum, 5-20 parts of artificial bezoar and 15-60 parts of liquorice.

Citation Information

Patent Citations

  • Chinese medicinal composition for treating common cold, acute and chronic tracheitis and preparation method thereof

    CN101327294A

  • Application of traditional Chinese medicine composition to preparation of medicine for preventing pulmonary heart disease

    CN108619372A

Cited By

  • External traditional Chinese medicine composition and external traditional Chinese medicine ointment with effects of promoting qi circulation, relaxing bowels, regulating cold and heat, ascending lucidity and descending turbid, preparation method and application of external traditional Chinese medicine composition and external traditional Chinese medicine ointment

    CN120732993A

  • External use traditional Chinese medicine composition with the effects of moving qi to dredge bowels, regulating cold and heat and ascending clear and descending turbid, external use traditional Chinese medicine ointment, preparation method and application

    CN120732993B